10-Q: Stimcell Energetics Reports Widening Losses, Going Concern Doubt

Stimcell Energetics Inc. reported a significant increase in net loss and a worsening working capital deficit for the six months ended November 30, 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• Stimcell Energetics Inc. reported a net loss of $575,350 for the six months ended November 30, 2025, a substantial increase from $206,427 in the same period last year.
• Operating expenses surged by 186.5% to $545,400, primarily driven by a 674.5% increase in general and administrative expenses to $303,082 and new research and development costs of $108,344.
• The company's working capital deficit worsened to $1,542,294 as of November 30, 2025, from $1,246,286 at May 31, 2025.
• Cash on hand increased to $46,159 from $14,581, largely due to $214,248 in financing from related parties.
• The company continues to rely heavily on related party financing, with total notes and advances due to related parties increasing to $708,923 from $469,874.
• Management has identified substantial doubt about the company's ability to continue as a going concern due to accumulated deficits and lack of profitable operations.
• Stimcell Energetics is redesigning its eBalance microcurrent device in partnership with ADM Tronics Unlimited, Inc., incurring $108,344 in R&D costs during the period.
• A new service agreement was signed with St. Boniface Hospital Albrechtsen Research Centre to study the eBalance device's effects on mitochondrial function, with the project expected to span approximately three months.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to significantly increased losses, a worsening working capital deficit, explicit 'going concern' doubt, heavy reliance on related party financing, and identified ineffective internal controls. While there are R&D efforts, the financial instability overshadows any operational progress.

Positives

• Cash balance increased to $46,159 as of November 30, 2025, from $14,581 at May 31, 2025.
• The company has initiated a new partnership with ADM Tronics Unlimited, Inc. to redesign its eBalance microcurrent device into a compact, affordable consumer unit.
• A research agreement with St. Boniface Hospital Albrechtsen Research Centre has been established to further define the physiological action of microcurrents, indicating ongoing scientific validation efforts.

Negatives

• Net loss significantly increased to $575,350 for the six months ended November 30, 2025, compared to $206,427 for the same period in 2024.
• Total operating expenses rose by 186.5% to $545,400, primarily due to a 674.5% increase in general and administrative expenses and new research and development costs.
• The working capital deficit worsened by 23.8% to $1,542,294 as of November 30, 2025.
• Accumulated deficit grew to $11,436,906, indicating a history of unprofitable operations.
• The company's disclosure controls and procedures were deemed not effective due to a lack of segregation of duties.
• Several related party loans, including two $30,000 notes from the CEO and a director, are in default since April 24, 2023.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to accumulated deficits and lack of profitable operations.
• The company is highly dependent on obtaining additional financing from directors, officers, promissory notes, and/or private placement of common stock to meet its obligations and fund operations.
• The current business operations are in an early development stage, with minimal revenue generation.
• Research and development as well as marketing plans require large capital expenditures, which the company currently lacks sufficient funding for.
• Disclosure controls and procedures were not effective due to a lack of segregation of duties, posing a risk to financial reporting integrity.

Future Outlook

Management intends to obtain additional funding by borrowing from its directors and officers, issuing promissory notes, and/or conducting private placements of common stock to support operations and the redesign of the eBalance microcurrent device. The company expects the eBalance redesign project to take approximately 22 to 34 weeks and cost between $62,500 and $127,000, though it has not yet been completed as of November 30, 2025. A new research project on mitochondrial function is expected to span approximately three months.

Management Comments

• "Operating results for the three and six months ended November 30, 2025, are not necessarily indicative of the results that can be expected for the year ending May 31, 2026."
• "Continuation as a going concern is dependent upon the ability of the Company to obtain the necessary financing to meet obligations and pay its liabilities arising from normal business operations when they come due and ultimately upon its ability to achieve profitable operations."
• "The outcome of these matters cannot be predicted with any certainty at this time and raises substantial doubt that the Company will be able to continue as a going concern."
• "Management is planning to support its operations as well as the redesign of the eBalance microcurrent device through equity or debt financing."
• "The Company's current business operations are in an early development stage and as such, its ability to generate revenue from the operations is very minimal."

Industry Context

Stimcell Energetics operates in the biotech sector, specifically focusing on microcurrent technology for general wellness and therapeutic applications. The company's efforts to redesign its eBalance device into a compact, affordable consumer unit align with a broader trend in the health and wellness industry towards accessible home-use medical and wellness devices. The research partnership with St. Boniface Hospital Albrechtsen Research Centre indicates a commitment to scientific validation, which is crucial for credibility in the biotech and medical device space. However, the company's significant financial challenges and early development stage suggest it is far from commercialization and faces intense competition from established players and well-funded startups in the health tech market.

Comparison to Industry Standards

• The company's lack of revenue generation and significant accumulated deficit of over $11.4 million are far below industry standards for a mature biotech company, indicating it is still in a very early, pre-commercialization stage.
• Reliance on related party financing for operational funding is not a sustainable long-term business model and is atypical for publicly traded companies with robust market access, unlike more established medical device companies such as Medtronic or Boston Scientific, which have diverse funding sources and strong revenue streams.
• The disclosure of ineffective internal controls due to lack of segregation of duties falls short of best practices for corporate governance and financial integrity, especially when compared to larger, more mature companies in the medical technology sector.
• While the R&D efforts for the eBalance device are positive, the project's delays and cost overruns (original estimate $62,500-$127,000, already spent $172,353) suggest challenges in project management and resource allocation, which could be a concern compared to more efficient R&D pipelines seen in successful biotech firms.

Corporate Governance

Related Party Transactions

• Amounts due to the CEO and President: $196,988 as of November 30, 2025 (unsecured, due on demand, no interest).
• Amounts due to the CFO: $5,615 as of November 30, 2025 (unsecured, due on demand, no interest).
• Amounts due to an entity controlled by a director: $343,844 as of November 30, 2025 (unsecured, due on demand, no interest).
• Management fees incurred to the CEO and President: $45,000 for the six months ended November 30, 2025.
• Consulting fees incurred to the CFO: $15,000 for the six months ended November 30, 2025.
• Consulting fees incurred to an entity controlled by a director: $54,195 for the six months ended November 30, 2025.
• Notes payable to Mr. Richard Jeffs (significant shareholder, father of CEO): $301,666 as of November 30, 2025, including $200,000 borrowed during the period under a 10% per annum credit line.
• Notes payable to Mr. David Jeffs (CEO, director): $49,891 as of November 30, 2025, with a $30,000 loan in default since April 24, 2023.
• Notes payable to a company of which Mr. David Jeffs is a director: $33,211 as of November 30, 2025.
• Notes payable to Mr. Amir Vahabzadeh (director, significant shareholder): $194,784 as of November 30, 2025, with a $30,000 note in default since April 24, 2023.
• Notes payable to Mr. Ahdoot (significant shareholder): $76,481 as of November 30, 2025.
• Notes payable to Mrs. Susan Jeffs (mother of CEO): $42,160 as of November 30, 2025, including $14,248 borrowed during the period under a 10% per annum credit line.
• Advances payable from an entity controlled by Mr. David Jeffs: $10,730 as of November 30, 2025 (non-interest-bearing, unsecured, due on demand).

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises and the issuance of shares for services. The substantial accumulated deficit and going concern doubt indicate a high risk of capital loss.
• **Creditors**: Related party creditors are providing significant financing, but the company's inability to generate revenue and increasing debt levels, including defaulted loans, pose a risk to repayment.
• **Employees**: The company's financial instability and going concern doubt could impact job security and future compensation, although specific employee numbers or impacts are not detailed.
• **Customers**: The delay in the eBalance device redesign project means potential customers will wait longer for the product, and the company's financial health could affect long-term product support.

Next Steps

• Continue redesigning the eBalance microcurrent device with ADM Tronics Unlimited, Inc.
• Conduct experiments with St. Boniface Hospital Albrechtsen Research Centre to assess eBalance stimulation effects on mitochondrial function over approximately three months.
• Management plans to secure additional funding through related party loans, promissory notes, and/or private placement of common stock.
• Address the identified ineffectiveness of disclosure controls and procedures due to lack of segregation of duties.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial increase in net loss, a worsening working capital deficit, and explicit 'going concern' doubt. Its operations are entirely funded by related party loans, some of which are in default, indicating an unsustainable financial model. The identified ineffective internal controls further erode confidence in financial reporting. While R&D efforts are underway, they are delayed and over budget, and the company has no revenue. These factors collectively point to a high risk of further value erosion and potential insolvency, making a 'strong sell' recommendation appropriate for any investor.

Keywords

Biotech, Microcurrent device, eBalance Technology, SEC filing, 10-Q, Financial results, Net loss, Going concern, Related party loans, Research and development, Corporate governance, Stimcell Energetics